Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma

References

• Barlogie B, Alexanian R, Dicke K A, Zagars G, Spitzer G, Jagannath S, Horowitz L. High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 868–872
   Google Scholar
• Cunningham D, Paz-Ares L, Gore M E, Malpas J, Hickish T, Nicholson M, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated multiple myeloma. J Clin Oncol 1994; 12: 759–763
   PubMed Web of Science ®Google Scholar
• Alexanian R, Dimopoulos M, Hester J, Delasalle K, Champlin R. Early myeloablative therapy for multiple myeloma. Blood 1994; 84: 4278–4282
   PubMed Web of Science ®Google Scholar
• Harousseau J L, Attal M, Divine M, Marit G, Leblond V, Stoppa A M, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. Blood 1995; 85: 3077–3085
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J L, Stoppa A M, Sotto J J, Fuzibet J G, Rossi J F, et al. Autologous bone marrow transplantation vs. conventional chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 9197
   Web of Science ®Google Scholar
• Child J A, Morgan G J, Davies F E, Owen R G, Bell S E, Hawkins K, et al. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883
   PubMed Web of Science ®Google Scholar
• Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T, Champlin R. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037–1043
   PubMed Web of Science ®Google Scholar
• Blade J, Esteve J, Rives S, Martinez C, Rovira M, Urbano-Ispizna A, et al. High-dose therapy autotransplantation intensification versus continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplant 2000; 26: 845–849
   PubMed Web of Science ®Google Scholar
• Nadal E, Gine E, Blade J, Esteve J, Rosinol L, Fernandez-Aviles F, et al. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplant 2004; 33: 61–64
   PubMed Web of Science ®Google Scholar
• Lahuerta J J, Martinez-Lopez J, Serna J D, Blade J, Grande C, Alegre A, et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000; 109: 438–446
   PubMed Web of Science ®Google Scholar
• Blade J, Samson D, Reece D, Apperley J, Bjoˇrkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated with high-dose therapy and haemopoetic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123
   PubMed Web of Science ®Google Scholar
• Chronic Leukaemia-Myeloma Task Force. National Cancer Institute: proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemother Rep 1973; 4: 145–158
   Google Scholar
• Nadal E, Gine E, Blade J, Esteve J, Rosinol L, Fernandez-Aviles F, et al. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplant 2004; 33: 61–64
   PubMed Web of Science ®Google Scholar
• Greipp P R, Lust J A, O'Fallon W M, Katzmann J A, Witzig T E, Kyle R A. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382–3387
   PubMed Web of Science ®Google Scholar
• Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, et al. Intergroupe Francophone du Myelome. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731–735
   PubMed Web of Science ®Google Scholar
• Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Uesole D H, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 and not with other karyotype abnormalities. Blood 1995; 86: 4250–4256
   PubMed Web of Science ®Google Scholar
• Fonseca R, Blood E, Rue M, Harrington D, Oken M M, Kyle R A, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569–4575
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J L, Facon T, Guilhot F, Doyen C, Fuzibet J G, et al. InterGroupe Francophone du Myelome. Single vs. double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502
   PubMed Web of Science ®Google Scholar
• Maloney D G, Molina A J, Sahebi F, Stockert-Goldstein K E, Sandmaier B M, Bensinger W, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447–3454
   PubMed Web of Science ®Google Scholar
• Richardson P G, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617
   PubMed Web of Science ®Google Scholar
• Yi Q, Desikan R, Barlogie B, Munshi N. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol 2002; 117: 297–305
   PubMed Web of Science ®Google Scholar
• Kwak L W, Neelapu S S, Bishop M R. Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion. Semin Oncol 2004; 31: 37–46
   PubMed Web of Science ®Google Scholar